Melt Pharmaceuticals Announces Dosing of Last Patient in Pivotal Phase 3 Study of Its Lead Product Candidate, Melt-300, for Needle- and Opioid-Free Sedation in Patients Undergoing Cataract Surgery
Melt製藥宣佈其主力產品候選藥物Melt-300關鍵第3階段研究中最後一位患者的投藥，用於在接受白內障手術的患者中進行無針無阿片類麻醉。
